TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A review published in Nutrients examined research on ergothioneine, an antioxidant found in mushrooms and other foods, and its possible effects on brain health. The review reports that some human studies link lower blood levels with poorer cognition, but those findings do not prove cause and effect, and evidence that eating mushrooms prevents neurodegenerative disease remains limited.
Researchers from the University of Rzeszow reviewed evidence on ergothioneine, a naturally occurring compound found in mushrooms and other foods, and its possible role in brain aging. The review, published in Nutrients, describes associations with cognition and promising laboratory and animal findings, but it does not establish that eating more mushrooms prevents dementia or protects people from neurodegenerative disease.
In their review, the authors examined observational studies, experiments in cells and animals, and a small number of human trials. They report that some observational research found lower circulating ergothioneine associated with poorer cognitive performance, mild cognitive impairment, frailty or Parkinson’s disease. The review also describes a longitudinal study of 470 adults who had no cognitive impairment at the outset; in that study, lower levels were associated with faster declines in several measured functions, including memory and attention.
The review authors caution that these results show relationships, not proof that low ergothioneine causes cognitive decline. They note that reduced levels could instead reflect changes associated with disease or the body’s use of antioxidants during oxidative stress. The review also reports conflicting evidence: one study linked higher serum ergothioneine with greater Alzheimer’s disease risk.
According to the review, cell and animal models have associated ergothioneine treatment with reduced oxidative stress and protection of neurons, as well as improved behavioral or cognitive measures in some disease models. The authors describe human findings as more limited. Trials have reported changes in subjective sleep quality or memory under particular conditions, but they do not demonstrate prevention or treatment of neurodegenerative disease. The review notes that some experiments used doses above typical dietary intake, and that a mushroom-extract trial cannot attribute any effect to ergothioneine alone.
What the Findings Mean for Diet
The review adds to research into whether diet-related compounds could help preserve brain function, an issue relevant to people concerned about cognitive decline and the effects of aging. The authors note that mushrooms contain ergothioneine, making them one dietary source of the compound. But the review does not show that increasing mushroom consumption prevents Alzheimer’s, Parkinson’s or other conditions.
The review’s authors emphasize that observational associations can be influenced by other differences between people, while results in animals or cells do not necessarily translate into a human benefit. The evidence may guide further research, but it is not a basis for presenting mushrooms or ergothioneine supplements as a proven way to protect the brain. The review does not establish a specific amount of mushrooms or ergothioneine for brain health.
Products Worth Considering
Therabody Theragun Relief Massage Gun, 3-Speed, Black
Bowflex SelectTech 840 Adjustable Kettlebell
Withings Sleep Under-Mattress Sleep Tracking Pad
As an affiliate, we earn on qualifying purchases.
How Ergothioneine Was Studied
The review describes ergothioneine as a thiol antioxidant present in mushrooms and some other foods. Oxidative stress is associated with neurodegenerative diseases and has been proposed as one contributor to damage in the nervous system. The authors discuss ergothioneine’s antioxidant activity as a possible explanation for reported effects, while noting that other biological mechanisms may be involved.
The review also covers research on whether ergothioneine affects inflammation and the body’s antioxidant response. Findings cited by the authors include effects on inflammatory signals in cultured microglia and in animal experiments. These are preclinical results; they do not establish that eating mushrooms produces the same effects in people. The authors describe the article as an assessment of the range and limitations of existing evidence, not a report of a new clinical trial.
What Human Studies Cannot Yet Show
The main unanswered question, according to the review authors, is whether ergothioneine itself can meaningfully reduce the risk of cognitive decline or neurodegenerative disease in people. The review identifies associations between blood levels and health outcomes, but those studies cannot determine whether low levels contribute to disease, result from it, or reflect other factors.
The review describes human trials as limited in duration and scope. Some reported improvements in subjective sleep measures or temporary changes in memory scores, while other biomarker trends were not statistically significant. The authors say the evidence does not establish a preventive dose, long-term safety or effectiveness, or whether benefits attributed to mushroom extracts came from ergothioneine rather than other compounds. The review also reports no evidence that eating additional mushrooms changes disease risk.
Evidence Needed From Longer Trials
The review’s findings point to a need for larger and longer human studies that can test whether ergothioneine intake or supplementation changes cognitive outcomes over time. Such trials would need to distinguish the effects of ergothioneine from those of other nutrients and compounds in mushrooms, and compare doses relevant to ordinary diets with supplement doses.
Until stronger clinical evidence is available, the review supports describing ergothioneine as a compound under investigation, not a proven safeguard against brain aging. Whether eating more mushrooms protects cognition remains unclear.
Key Questions
Does this review show that mushrooms prevent dementia?
No. The review summarizes research on ergothioneine but does not establish that eating mushrooms prevents dementia or neurodegenerative disease.
What is ergothioneine?
The review describes ergothioneine as a naturally occurring antioxidant compound found in mushrooms and other foods. Researchers are studying its possible effects on oxidative stress, inflammation and brain function.
Why are lower blood levels linked with poorer cognition?
Some observational studies summarized in the review found an association between lower ergothioneine levels and poorer cognitive measures. They cannot show whether low levels contribute to decline or are a result of disease-related changes or other factors.
Do supplements have proven brain-health benefits?
The evidence summarized in the review does not establish that ergothioneine supplements prevent or treat neurodegenerative disease. The authors describe human trials as limited, with some reporting subjective or short-term outcomes.
Source: news-medical.net
